Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

Axonics, founded in 2013, is renowned for developing less invasive treatments for bladder and bowel issues, including a neurostimulator with a 20-year battery life. Boston Scientific, a major ...

Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a ...

Axonics Modulation Technologies ( (AXNX) ) has released its Q3 earnings. Here is a breakdown of the information Axonics Modulation Technologies ...

BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.

Boston Scientific acquires Axonics in a $3.7B deal, enhancing its urology portfolio and expanding into sacral neuromodulation ...